Kamada Receives FDA Approval for In-House Rabies Virus Neutralization Testing Laboratory

Kamada Ltd. recently announced that the U.S. Food and Drug Administration (FDA) has approved its new in-house Rabies Virus Neutralization Testing (RVNT) laboratory. This approval allows Kamada to independently conduct critical testing required for the release of its rabies immunoglobulin product, KAMRAB®, to the market.

The establishment of this in-house RVNT laboratory streamlines Kamada’s quality control process. Before this approval, the company had to rely on external laboratories for RVNT testing, which could lead to delays in product release. With the in-house lab, Kamada gains greater control over the testing timeline, potentially accelerating the availability of KAMRAB® to patients who need it. The company anticipates that this capability will also lead to cost savings associated with outsourcing this essential testing.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI